Case Study: Biogazelle advances lncRNA cancer research with Illumina RNA-Seq and TruSeq RNA Exome

Biogazelle expands RNA-Seq discovery with Illumina, capturing 50,000 lncRNA targets

Biogazelle, a company specializing in RNA analysis and experimental design services, faced the challenge of studying long non-coding RNAs (lncRNAs) in highly fragmented cancer samples like FFPE tissues and liquid biopsies. Many lncRNAs lack polyA tails, making them difficult to capture with standard sequencing methods. To overcome this, Biogazelle utilized Illumina's NextSeq 500 System and the TruSeq RNA Exome library prep solution.

The Illumina solution enabled Biogazelle to efficiently sequence total RNA, including the previously hard-to-detect lncRNAs without polyA tails. This provided high-quality data from their challenging sample types. As a result, Biogazelle can now identify and measure specific lncRNAs that certain cancer cells are "addicted" to, which is crucial for developing new diagnostics and targeted therapeutics, solidifying their position as world experts in the field.

Biogazelle